SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Visa to Move European Headquarters to London’s Canary Wharf 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
